Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives of this study are to assess the efficacy (SVR12) HCV RNA < lower limit of quantification (LLOQ) 12 weeks following 12 weeks of treatment of the ABT-493/ABT-530 combination regimen and the safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen compared to placebo, in adults with chronic HCV genotype (GT) 2 infection without underlying cirrhosis.
Critère d'inclusion
- Chronic HCV Infection